

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/002108 A2

(51) International Patent Classification⁷: **A61K 31/00**,
31/404, 31/506, 31/505, 31/519, 31/517

(21) International Application Number: PCT/IB02/03301

(22) International Filing Date: 28 June 2002 (28.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/301,410 29 June 2001 (29.06.2001) US

(71) Applicant (for all designated States except US): **AB SCI-
ENCE** [FR/FR]; 3, avenue Georges V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain**
[FR/FR]; 22 bis, passage Dauphine, F-75006 Paris (FR).
KINET, Jean-Pierre [FR/US]; 2 Hunt Road, Lexington,
MA 02173 (US).

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regim-
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF TYROSINE KINASE INHIBITORS FOR TREATING INFLAMMATORY DISEASES

(57) Abstract: The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.



WO 03/002108 A2

Use of tyrosine kinase inhibitors for treating inflammatory diseases

The present invention relates to a method for treating inflammatory diseases such as
5 rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a
human in need of such treatment, more particularly a non-toxic, selective and potent c-
kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells
cultured in presence of IL-3.

10 Millions of people are afflicted with rheumatoid arthritis in the USA alone, which
represent approximately 1% of the total adult population (Mitchell, D. 1985.
Rheumatoid Arthritis, eds. J.B. Lippincott Co., Philadelphia, pp. 133-150). This
progressive inflammatory disease is very important both socially and economically
because it leads to the disabling and extensive suffering of individuals. The distribution
15 of affected and deformed joints typically involves the small articulations of the hands
and feet, although the larger appendicular joints like the shoulders and hips are often
affected in established disease.

Current methods for treating rheumatoid arthritis include administration of non-steroidal
20 anti-inflammatory drugs such as acetylsalicylic acid (aspirin), ibuprofen, naproxen, cox2
inhibitors and other agents such as penicillamine, methotrexate, cytotoxic agents (e.g.,
azothioprine), 4-aminoquinoline agents, and immunomodulators. However, no
satisfactory treatment is available as of today. In addition, many of the therapeutic agents
administered to alleviate pain and inflammation associated with the disease, such as
25 disease-modifying antirheumatic drugs (DMARDs) and non-steroidal anti-inflammatory
agents (NSAIDs), produce intolerable side effects. The use of nonspecific
immunosuppressive drugs which suppress the entire immune system has also been

proposed but it increases the risk of infection. Furthermore, prolonged use of such drugs can entail severe toxic side effects and is only partially effective in mitigating symptoms of rheumatoid arthritis.

- 5 Therefore, improved treatments of rheumatoid arthritis, which can suppress symptoms such as inflammation, swelling, abnormal neovascularization, bone erosion, or cartilage erosion are needed.

The cause of rheumatoid arthritis remains elusive but it is now generally accepted that
10 infectious agents or toxins, genetic susceptibility, and immune or autoimmune responses play direct or indirect roles. After initiation of the disease process, it is believed that activated T cells and their products are responsible for the progressive destruction of articular cartilage and sub-chondral bone that is characteristic of rheumatoid arthritis.

The symptoms of the disease result from a massive increase in the number of cells lining
15 the synovium of the joint. The various cell types which are present include type A synoviocytes, which have the characteristics of monocytes or terminally differentiated macrophages, and type B synoviocytes which are fibroblast-like. As these cells increase in number, the continuous inflammation causes initial symptoms. Eventually, local release of enzymes by the synovial internal lining degrade the extracellular matrix and
20 cause deformity. Panayi et al, 1992, Arth. Rheum., 35, pp.729-735 mentioned that rheumatoid factors is caused by a cell-mediated process involving T cells, antigen-presenting cells (APC), macrophages, synoviocytes, and cytokines. T cells (Panayi et al., 1992, Arthritis Rheum. 35, 729-735), B cells (Zvaifler, 1973, Adv. Immunol. 265, 265-336), and other leukocytes such as dendritic cells, macrophages and neutrophils (Thomas
25 and Lipsky, 1996, Arthritis Rheum. 39, 183-190) have been shown to play a role the pathogenesis of this inflammatory disease. Rheumatoid arthritis is also generally considered an autoimmune disease that is thought to be associated with activity of

autoreactive T cells (Harris E., 1990, The New England Journal of Medicine, 322: 1277-1289).

Cytokines have also been indicated as being implicated in the pathophysiology of rheumatoid arthritis. Tumor necrosis factor (TNF-a) has received attention because it is consistently found in synovium of patients suffering from rheumatoid arthritis. In addition, anti-human TNF was demonstrated to prevent the development of arthritis in a transgenic human TNF-a mouse model. Elliott et al. (Arthritis Rheum. 1993, 36, 1681-1690) used chimeric (mouse-human) antibodies to TNF-a to treat patients with active rheumatoid arthritis. But, TNF-a might not be the only factor responsible for this inflammatory disease.

Therefore, there is a need for alternative treatments of these diseases that would be more effective on the long term in regards to the above mentioned observations and which would be well tolerated especially in respect to repeated administration.

In connection with the invention, we examined the distribution of mast cell subsets and their density in synovium from normal subjects and from patients with rheumatoid arthritis (RA). In normal synovium, the majority of mast cells belongs to the MCTC subset, outnumbering MCT cells by 5:1. The mean density of mast cells was significantly increased in RA synovia compared with normal synovia. In RA, both subsets expanded and were associated with infiltrating inflammatory cells or with regions of highly cellular fibrous tissue (mainly MCTC). In addition, a correlation was observed between clinical parameters of activity or progression of rheumatoid disease and the density of MCTC cells, especially the density in the superficial layer of synovium.

As a result, MCTC mast cells expand in RA, associate with regions of "active" fibrosis, and correlate with parameters of disease activity or progression of RA. These findings implicate the MCTC subset of mast cells in the pathologic mechanisms that mediate
5 tissue damage in RA.

Mast cells (MC) are tissue elements derived from a particular subset of hematopoietic stem cells that express CD34, c-kit and CD13 antigens (Kirshenbaum et al, Blood. 94: 2333-2342, 1999 and Ishizaka et al, Curr Opin Immunol. 5: 937-43, 1993). Immature
10 MC progenitors circulate in the bloodstream and differentiate in tissues. These differentiation and proliferation processes are under the influence of cytokines, one of utmost importance being Stem Cell Factor (SCF), also termed Kit ligand (KL), Steel factor (SL) or Mast Cell Growth Factor (MCGF). SCF receptor is encoded by the protooncogene c-kit, that belongs to type III receptor tyrosine kinase subfamily (Boissan
15 and Arock, J Leukoc Biol. 67: 135-48, 2000). This receptor is also expressed on others hematopoietic or non hematopoietic cells. Ligation of c-kit receptor by SCF induces its dimerization followed by its transphosphorylation, leading to the recruitment and activation of various intracytoplasmic substrates. These activated substrates induce multiple intracellular signaling pathways responsible for cell proliferation and activation
20 (Boissan and Arock, 2000). Mast cells are characterized by their heterogeneity, not only regarding tissue location and structure but also at the functional and histochemical levels (Aldenberg and Enerback., Histochem. J. 26: 587-96, 1994 ; Bradding et al. J Immunol. 155: 297-307, 1995 ; Irani et al, J Immunol. 147: 247-53, 1991 ; Miller et al, Curr Opin Immunol. 1: 637-42, 1989 and Welle et al, J Leukoc Biol. 61: 233-45, 1997).

25

In connection with the invention, it is proposed that mast cells play a crucial role in the pathogenesis of inflammatory diseases associated with mast cells, such as rheumatoid

arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, in that they produce a large variety of mediators categorized here into three groups:

- 5 - preformed granule-associated mediators (histamine, proteoglycans, and neutral proteases),
- lipid-derived mediators (prostaglandins, thromboxanes and leucotrienes),
- and various cytokines (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF- α , GM-CSF, MIP-1a, MIP-1b and IFN- γ).

10 Then, liberation by activated mast cells of mediators (TNF- α , leucotrienes, prostaglandines etc...) can induce these inflammatory diseases. In addition, mast cells activate T cells and macrophages, which further contributes to the inflammation and destruction process observed for example in rheumatoid arthritis.

15 Therefore, the invention provides a new therapeutic strategy aimed at blocking the activation of mast cells involved in RA.

In US 6,211,228, tryptase inhibitors are proposed for the prevention and treatment of mast-cell mediated inflammatory disorders and in US 5,861,264 anti-tryptase detection
20 is used as a diagnostic for inflammatory diseases. However, decreasing the activity of free tryptase released by activated mast cells is not sufficient to block chain reactions caused by the others mast cells released factors mentioned above.

In contrast, the present invention proposes to use c-kit specific kinase inhibitors to
25 inhibit mast cell proliferation, survival and activation. A new route for treating

inflammatory diseases is provided, which consists of destroying mast cells playing a role in the pathogenesis of these disorders. It has been found that tyrosine kinase inhibitors and more particularly c-kit inhibitors are especially suited to reach this goal.

5 **Description**

The present invention relates to a method for treating inflammatory diseases comprising administering a tyrosine kinase inhibitor to a mammal in need of such treatment.

10 Tyrosine kinase inhibitors are selected for example from bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds (US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and
15 benzylphosphonic acid compounds (WO 91/15495), pyrimidine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504, US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline
20 derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940) and aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758).

Preferably, said tyrosine kinase inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

25


In another embodiment, the invention is directed to a method for treating inflammatory diseases comprising administering a c-kit inhibitor to a mammal in need of such treatment.

Preferably, said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor. Such inhibitors can be selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

Among preferred compounds, it is of interest to focus on pyrimidine derivatives such as N-phenyl-2-pyrimidine-amine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4-thienyl-2-(1H)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,039), aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758), 4-anilinoquinazoline compounds (US 4,464,375), and 4-thienyl-2-(1H)-quinazolones (US 3,551,427).


20

So, preferably, the invention relates to a method for treating inflammatory diseases comprising administering a non toxic, potent and selective c-kit inhibitor. Such inhibitor can be selected from pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives of formula I :




wherein the R1, R2, R3, R13 to R17 groups have the meanings depicted in EP 564 409 B1, incorporated herein in the description.

- 5 Preferably, the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula II :



- 10 Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;
 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;
 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least
 15 one basic site, such as an amino function.

Preferably, R7 is the following group :



Among these compounds, the preferred are defined as follows :

R1 is a heterocyclic group, especially a pyridyl group,


R2 and R3 are H,

5 R4 is a C1-C3 alkyl, especially a methyl group,

R5 and R6 are H,


and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one

basic site, such as an amino function, for example the group :



Therefore, in a preferred embodiment, the invention relates to a method for treating inflammatory diseases comprising the administration of an effective amount of the compound known in the art as CGP57148B :

15 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2-ylamino]phényl]-benzamide corresponding to the following formula :



20 The preparation of this compound is described in example 21 of EP 564 409 and the β -form, which is particularly useful is described in WO 99/03854.

Alternatively, the c-kit inhibitor can be selected from :

- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds, quinazoline derivatives,
- and quinaxolines, such as 2-phényl-quinaxoline derivatives, for example 2-phenyl-
5 6,7-dimethoxy quinaxoline.

In a preferred aspect, the invention contemplated the method mentioned above, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

10

The expression “inflammatory diseases” refers herein to inflammatory diseases associated with mast cells, such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, which are embraced by the invention.

15

In a further embodiment, c-kit inhibitors as mentioned above are inhibitors of activated c-kit. In frame with the invention, the expression “activated c-kit” means a constitutively activated-mutant c-kit including at least one mutation selected from point mutations, deletions, insertions, but also modifications and alterations of the natural c-kit sequence (SEQ ID N°1). Such mutations, deletions, insertions, modifications and alterations can
20 occur in the transphosphorylase domain, in the juxtamembrane domain as well as in any domain directly or indirectly responsible for c-kit activity. The expression “activated c-kit” also means herein SCF-activated c-kit. Preferred and optimal SCF concentrations for activating c-kit are comprised between 5.10^{-7} M and 5.10^{-6} M, preferably around
25 2.10^{-6} M. In a preferred embodiment, the activated-mutant c-kit in step a) has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants. In another preferred embodiment, the activated-mutant c-kit in step a)

has a deletion in the juxtamembrane domain of c-kit. Such a deletion is for example between codon 573 and 579 called c-kit d(573-579). The point mutation V559G proximal to the juxtamembrane domain c-kit is also of interest.

5 In this regard, the invention contemplates a method for treating inflammatory diseases comprising administering to a mammal in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested;
- 10 under conditions allowing the components (i) and (ii) to form a complex,
- b) selecting compounds that inhibit activated c-kit,
- c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

15 This screening method can further comprise the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are also capable of inhibiting SCF-activated c-kit wild.

Alternatively, in step a) activated c-kit is SCF-activated c-kit wild.

20

A best mode for practicing this method consists of testing putative inhibitors at a concentration above 10 μ M in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40 μ M.

25 In step c), IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

Examples of IL-3 dependent cells include but are not limited to :

- cell lines naturally expressing and depending on c-kit for growth and survival. Among such cells, human mast cell lines can be established using the following procedures :
normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence
5 allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoietic cells by means of antibodies.

This technique is advantageous because it does not induce cellular mortality and the genetic transfer is stable and gives satisfactory yields (around 20 %). Pure normal human mast cells can be routinely obtained by culturing precursor cells originating from blood
10 obtained from human umbilical vein. In this regard, heparinated blood from umbilical vein is centrifuged on a Ficoll gradient so as to isolate mononucleated cells from other blood components. CD34+ precursor cells are then purified from the isolated cells mentioned above using the immunomagnetic selection system MACS (Miltenyi biotech). CD34+ cells are then cultured at 37°C in 5 % CO₂ atmosphere at a concentration of 10⁵
15 cells per ml in the medium MCCM (α -MEM supplemented with L-glutamine, penicillin, streptomycin, 5 10⁻⁵ M β -mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF. The medium is changed every 5 to 7 days. The percentage of mast cells present in the culture is assessed each week, using May-Grünwal Giemsa or Toluidine blue coloration. Anti-tryptase antibodies can also be
20 used to detect mast cells in culture. After 10 weeks of culture, a pure cellular population of mast cells (> 98 %) is obtained.

It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above. The cDNA of human c-kit has been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351. The coding part of

c-kit (3000 bp) can be amplified by PCR and cloned, using the following oligonucleotides :

- 5'AAGAAGAGATGGTACCTCGAGGGGTGACCC3' (SEQ ID No2) sens
- 5'CTGCTTCGCGGCCGCGTTAACTCTTCTCAACCA3' (SEQ ID No3)

5 antisens

The PCR products, digested with NotI and XhoI, has been inserted using T4 ligase in the pFlag-CMV vector (SIGMA), which vector is digested with NotI and XhoI and dephosphorylated using CIP (Biolabs). The pFlag-CMV-c-kit is used to transform bacterial clone XL1-blue. The transformation of clones is verified using the following

10 primers :

- 5'AGCTCGTTTAGTGAACCGTC3' (SEQ ID No4) sens,
- 5'GTCAGACAAAATGATGCAAC3' (SEQ ID No5) antisens.

Directed mutagenesis is performed using relevant cassettes is performed with routine and common procedure known in the art..

15 The vector Migr-1 (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells. This vector is advantageous because it contains the sequence coding for GFP at the 3' and of an IRES. These features allow to select cells infected by the retrovirus using direct analysis with a fluorocytometer. As mentioned above, the N-terminal sequence of c-kit c-DNA can be modified so as to introduce a Flag
20 sequence that will be useful to discriminating heterogeneous from endogenous c-kit.

Other IL-3 dependent cell lines that can be used include but are not limited to:

- BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood
25 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329.

- IC-2 mouse cells expressing either c-kit^{WT} or c-kit^{D814Y} are presented in Piao et al, (1996), Proc. Natl. Acad. Sci. USA 93, 14665-14669.

IL-3 independent cell lines are :

- 5 - HMC-1, a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).
- 10 - P815 cell line (mastocytoma naturally expressing c-kit mutation at the 814 position) has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.

The extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *in vivo*. In case it is measured *in vivo*, cell lines expressing an activated-mutant c-kit, which
15 has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants, are preferred.

Example of cell lines expressing an activated-mutant c-kit are as mentioned.

- 20 In another preferred embodiment, the method further comprises the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below 1 μ M. This can be measured *in vitro* or *in vivo*.

In vivo testing may comprise measuring the ability of the tyrosine kinase inhibitors to
25 alleviate arthritis symptoms in transgenic mouse model of arthritis that spontaneously develops a disease with many of the characteristics of rheumatoid arthritis in humans

(Kouskoff et al., 1996 and US 5,675,060). Alternatively, transgenic human TNF- α mouse model can be used.

Therefore, compounds are identified and selected according to the method described
5 above are potent, selective and non-toxic c-kit wild inhibitors.

Alternatively, the screening method as defined above can be practiced *in vitro*. In this regard, the inhibition of mutant-activated c-kit and/or c-kit wild can be measured using standard biochemical techniques such as immunoprecipitation and western blot.
10 Preferably, the amount of c-kit phosphorylation is measured.

In a still further embodiment, the invention contemplates a method for treating inflammatory diseases as depicted above wherein the screening comprises :

- a) performing a proliferation assay with cells expressing a mutant c-kit (for example in
15 the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an $IC_{50} < 10 \mu M$, by measuring the extent of cell death,
- b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured
20 in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
- c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an $IC_{50} < 10 \mu M$, preferably an $IC_{50} < 1 \mu M$, by measuring the
25 extent of cell death.

Here, the extent of cell death can be measured by ³H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.

- 5 The method according to the invention includes preventing, delaying the onset and/or treating inflammatory diseases in human.

Therefore, the invention embraces the use of the compounds defined above to manufacture a medicament for treating inflammatory diseases such as rheumatoid
10 arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, polyarthritis, and other arthritic conditions as well as pain associated with these inflammatory diseases.

The pharmaceutical compositions utilized in this invention may be administered by any
15 number of routes including, but not limited to oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain
20 suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

25

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated

as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical compositions suitable for use in the invention include compositions
5 wherein c-kit inhibitors are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or
10 experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. As mentioned above, a tyrosine kinase inhibitor and more particularly a c-kit
15 inhibitor according to the invention is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

The invention also concerns a product comprising a tyrosine kinase inhibitor as defined above and at least one anti-inflammatory compound selected from the group consisting
20 of acetylsalicylic acid (aspirin), ibuprofen, naproxen, and cox2 inhibitors.

Utility of the invention will further ensue from the detailed description below.

Exemple 1: Use of 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2 ylamino]phényl]-benzamide for treating arthritis.
25

Protocol Treatment

The mice were pretreated with the compound at different concentrations for two days (day-2, day -1) before induction of arthritis. Arthritis was induced by ip injection of 150 µl serum at days 0 and 2. The treatment with the compound at different concentration was continued during the course of the disease. The control mice were injected with acid PBS before the induction of arthritis and during the course of the disease. Ankle thickness and arthritis score was evaluated for 12 days. Arthritis Score : Sum of scores of each limb (0 no disease; 0.5 mild swelling of paw or of just a few digits; 1 clear joint inflammation; max score=4). The results are presented in **Figures 1 and 2**. Table 1 shows the number of mice used in this study.

Table 1

Compound concentration	BalbC/cj	C57Bl/6
0.5 mg	2	
1 mg		2
1.5 mg		2
2mg		
3 mg	2	

Controls of the treated mice	BalbC/cj	C57Bl/6
0.5 mg	3	
1 mg		2
1.5 mg		2
2 mg		
*3 mg	2	

*The dose of 3mg was lethal.

The compound was dissolved in acid PBS solution, pH 3. In order to rule out any toxic effect of this low pH studies on the natural activation of B and T cells was monitored. 3 mice were injected with acid PBS for 4 days and compared to 3 control mice that were injected with PBS.

Histology

At the end of the experiment the hind limbs were collected. The skin of the limb was removed and the limbs were subsequently fixed in 2% paraformaldehyde.

CLAIMS

1. A method for treating inflammatory diseases comprising administering a tyrosine kinase inhibitor to a mammal in need of such treatment.

5

2. A method according to claim 1, wherein said tyrosine kinase inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

3. A method for treating inflammatory diseases comprising administering a c-kit inhibitor to a mammal in need of such treatment.

10

4. A method according to claim 3, wherein said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor.

5. A method according to claim 4, wherein said inhibitor is selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

15


20

6. A method according to claim 4, wherein said inhibitor is selected from the group consisting of :

25

- pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds,
- and quinazoline derivatives.

7. A method according to one of claims 1 to 6, wherein said inhibitor is selected from the group consisting of N-phenyl-2-pyrimidine-amine derivatives having the formula II :




5

Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;

10 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, preferably the following group :



15 8. A method according to claim 7, wherein said inhibitor is the 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2 ylamino]phényl]-benzamide.

9. A method according to one of claims 3 to 8, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

20 10. A method according to one of claims 3 to 9, wherein said c-kit inhibitor is an inhibitor of activated c-kit.

11. A method according to claim 10, wherein said activated c-kit inhibitor is capable of inhibiting SCF-activated c-kit.

12. A method according to claim 10, wherein said inhibitor is capable of inhibiting
5 constitutively activated-mutant c-kit.

13. A method for treating inflammatory diseases comprising administering to a mammal in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- 10 a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
b) selecting compounds that inhibit activated c-kit,
c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

15

14. A method according to claim 13, wherein the screening method further comprises the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit, which are also capable of inhibiting SCF-activated c-kit wild.

20

15. A method according to claim 13, wherein activated c-kit is SCF-activated c-kit wild in step a).

16. A method according to one of claims 13 to 15, wherein putative inhibitors are tested
25 at a concentration above 10 μ M in step a).

17. A method according to one of claims 13 to 16, wherein IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

5 18. A method according to claim 17, wherein IL-3 dependent cells are selected from the group consisting of mast cells, transfected mast cells, BaF3, and IC-2.

19. A method according to one of claims 13 to 17, wherein the extent to which component (ii) inhibits activated c-kit is measured *in vitro* or *in vivo*.

10

20. A method according to one of claims 13 to 17, further comprising the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below 1 μ M.

15 21. A method according to claim 20, wherein the testing is performed *in vitro* or *in vivo*.

22. A method according to one of claims 13 to 21, wherein the inhibition of mutant-activated c-kit and/or c-kit wild is measured using standard biochemical techniques such as immunoprecipitation and western blot.

20

23. A method according to one of claims 13 to 22, wherein the amount of c-kit phosphorylation is measured.

24. A method according to one of claims 13 to 23, wherein identified and selected
25 compounds are potent, selective and non-toxic c-kit wild inhibitors.

25. A method for treating inflammatory diseases comprising administering to a mammal in need of such treatment a c-kit inhibitor obtainable by a screening method comprising :

a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an $IC_{50} < 10 \mu M$, by measuring the extent of cell death,

5 b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,

10 c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an $IC_{50} < 10 \mu M$, preferably an $IC_{50} < 1 \mu M$, by measuring the extent of cell death.

26. A method according to claim 25, wherein the extent of cell death is measured by ³H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide.

27. A method according to one of claims 1 to 26 for preventing, delaying the onset and/or treating inflammatory diseases in human.

20

28. A method according to one of claims 1 to 26 for preventing, delaying the onset and/or treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, polyarthritis, and other arthritic conditions as well as pain associated with these
25 inflammatory diseases.

29. Use of a c-kit inhibitor to manufacture a medicament for treating inflammatory diseases.

30. A composition suitable for oral administration comprising a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the treatment of inflammatory disorders such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, 5 polyarthritis, and other arthritic conditions as well as pain associated with these inflammatory diseases.

31. A composition suitable for topical, intranasal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, 10 intraperitoneal, enteral, sublingual, or rectal administration comprising a tyrosine kinase inhibitor, more particularly a c-kit inhibitor for the treatment of inflammatory disorders such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, polyarthritis, and other arthritic conditions as well as pain associated with these inflammatory diseases.

1 / 2

Ankle thickness (1.5 mg/daily)




FIGURE 1A

Ankle thickening (1.5 mg/daily)




FIGURE 1B

Clinical Index




FIGURE 1C

2 / 2

Ankle thickness (0.5mg/daily)




FIGURE 2A

Ankle thickening (0.5mg/daily)




FIGURE 2B

Clinical Index




FIGURE 2C

SEQUENCE LISTING

<110> AB Science

<120> Use of tyrosine kinase inhibitors for treating
inflammatory diseases

<130> D19697

<150> US 60/301,410

<151> 2001-06-29

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 976

<212> PRT

<213> Homo sapiens

<220>

<223> Human c-kit

<400> 1

Met Arg Gly Ala Arg Gly Ala Trp Asp Phe Leu Cys Val Leu Leu Leu
1 5 10 15Leu Leu Arg Val Gln Thr Gly Ser Ser Gln Pro Ser Val Ser Pro Gly
20 25 30Glu Pro Ser Pro Pro Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val
35 40 45Arg Val Gly Asp Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val
50 55 60Lys Trp Thr Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn
65 70 75 80Glu Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr Thr
85 90 95Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe Val Arg
100 105 110Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu Tyr Gly Lys Glu
115 120 125Asp Asn Asp Thr Leu Val Arg Cys Pro Leu Thr Asp Pro Glu Val Thr
130 135 140Asn Tyr Ser Leu Lys Gly Cys Gln Gly Lys Pro Leu Pro Lys Asp Leu
145 150 155 160Arg Phe Ile Pro Asp Pro Lys Ala Gly Ile Met Ile Lys Ser Val Lys
165 170 175Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly
180 185 190

Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe
 195 200 205
 Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg
 210 215 220
 Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val Ser Ser
 225 230 235 240
 Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser Gln Thr Lys Leu Gln
 245 250 255
 Glu Lys Tyr Asn Ser Trp His His Gly Asp Phe Asn Tyr Glu Arg Gln
 260 265 270
 Ala Thr Leu Thr Ile Ser Ser Ala Arg Val Asn Asp Ser Gly Val Phe
 275 280 285
 Met Cys Tyr Ala Asn Asn Thr Phe Gly Ser Ala Asn Val Thr Thr Thr
 290 295 300
 Leu Glu Val Val Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn
 305 310 315 320
 Thr Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu
 325 330 335
 Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr Met Asn
 340 345 350
 Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys Ser Glu Asn Glu
 355 360 365
 Ser Asn Ile Arg Tyr Val Ser Glu Leu His Leu Thr Arg Leu Lys Gly
 370 375 380
 Thr Glu Gly Gly Thr Tyr Thr Phe Leu Val Ser Asn Ser Asp Val Asn
 385 390 395 400
 Ala Ala Ile Ala Phe Asn Val Tyr Val Asn Thr Lys Pro Glu Ile Leu
 405 410 415
 Thr Tyr Asp Arg Leu Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly
 420 425 430
 Phe Pro Glu Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln
 435 440 445
 Arg Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser
 450 455 460
 Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile Asp Ser
 465 470 475 480
 Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys Lys Ala Tyr Asn Asp
 485 490 495
 Val Gly Lys Thr Ser Ala Tyr Phe Asn Phe Ala Phe Lys Gly Asn Asn
 500 505 510
 Lys Glu Gln Ile His Pro His Thr Leu Phe Thr Pro Leu Leu Ile Gly

515					520					525					
Phe	Val	Ile	Val	Ala	Gly	Met	Met	Cys	Ile	Ile	Val	Met	Ile	Leu	Thr
530						535					540				
Tyr	Lys	Tyr	Leu	Gln	Lys	Pro	Met	Tyr	Glu	Val	Gln	Trp	Lys	Val	Val
545					550					555					560
Glu	Glu	Ile	Asn	Gly	Asn	Asn	Tyr	Val	Tyr	Ile	Asp	Pro	Thr	Gln	Leu
				565					570					575	
Pro	Tyr	Asp	His	Lys	Trp	Glu	Phe	Pro	Arg	Asn	Arg	Leu	Ser	Phe	Gly
			580					585					590		
Lys	Thr	Leu	Gly	Ala	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Ala	Thr	Ala
		595					600					605			
Tyr	Gly	Leu	Ile	Lys	Ser	Asp	Ala	Ala	Met	Thr	Val	Ala	Val	Lys	Met
	610					615					620				
Leu	Lys	Pro	Ser	Ala	His	Leu	Thr	Glu	Arg	Glu	Ala	Leu	Met	Ser	Glu
625					630					635					640
Leu	Lys	Val	Leu	Ser	Tyr	Leu	Gly	Asn	His	Met	Asn	Ile	Val	Asn	Leu
				645					650					655	
Leu	Gly	Ala	Cys	Thr	Ile	Gly	Gly	Pro	Thr	Leu	Val	Ile	Thr	Glu	Tyr
			660					665					670		
Cys	Cys	Tyr	Gly	Asp	Leu	Leu	Asn	Phe	Leu	Arg	Arg	Lys	Arg	Asp	Ser
		675					680					685			
Phe	Ile	Cys	Ser	Lys	Gln	Glu	Asp	His	Ala	Glu	Ala	Ala	Leu	Tyr	Lys
		690				695					700				
Asn	Leu	Leu	His	Ser	Lys	Glu	Ser	Ser	Cys	Ser	Asp	Ser	Thr	Asn	Glu
705					710					715					720
Tyr	Met	Asp	Met	Lys	Pro	Gly	Val	Ser	Tyr	Val	Val	Pro	Thr	Lys	Ala
				725					730					735	
Asp	Lys	Arg	Arg	Ser	Val	Arg	Ile	Gly	Ser	Tyr	Ile	Glu	Arg	Asp	Val
			740					745					750		
Thr	Pro	Ala	Ile	Met	Glu	Asp	Asp	Glu	Leu	Ala	Leu	Asp	Leu	Glu	Asp
		755				760						765			
Leu	Leu	Ser	Phe	Ser	Tyr	Gln	Val	Ala	Lys	Gly	Met	Ala	Phe	Leu	Ala
		770				775					780				
Ser	Lys	Asn	Cys	Ile	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Ile	Leu	Leu
785					790					795					800
Thr	His	Gly	Arg	Ile	Thr	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp
				805					810					815	
Ile	Lys	Asn	Asp	Ser	Asn	Tyr	Val	Val	Lys	Gly	Asn	Ala	Arg	Leu	Pro
			820					825					830		
Val	Lys	Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asn	Cys	Val	Tyr	Thr	Phe
		835					840					845			

Glu Ser Asp Val Trp Ser Tyr Gly Ile Phe Leu Trp Glu Leu Phe Ser
 850 855 860
 Leu Gly Ser Ser Pro Tyr Pro Gly Met Pro Val Asp Ser Lys Phe Tyr
 865 870 875 880
 Lys Met Ile Lys Glu Gly Phe Arg Met Leu Ser Pro Glu His Ala Pro
 885 890 895
 Ala Glu Met Tyr Asp Ile Met Lys Thr Cys Trp Asp Ala Asp Pro Leu
 900 905 910
 Lys Arg Pro Thr Phe Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile
 915 920 925
 Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro
 930 935 940
 Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val
 945 950 955 960
 Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp Val
 965 970 975

<210> 2
 <211> 30
 <212> DNA
 <213> Homo sapiens

<220>
 <223> Primer

<400> 2
 aagaagagat ggtacctcga ggggtgaccc

30

<210> 3
 <211> 33
 <212> DNA
 <213> Homo sapiens

<220>
 <223> Primer

<400> 3
 ctgcttcgcg gccgcgttaa ctcttctcaa cca

33

<210> 4
 <211> 20
 <212> DNA
 <213> Homo sapiens

<220>
 <223> Primer

<400> 4
agctcggtta gtgaaccgtc

20

<210> 5
<211> 20
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 5
gtcagacaaa atgatgcaac

20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/002108 A3

(51) International Patent Classification⁷: **A61K 31/00**,
31/404, 31/506, 31/505, 31/519, 31/517, 31/498, 31/415,
31/4709, 31/015, 31/095, 31/66, A61P 29/00

(21) International Application Number: PCT/IB02/03301

(22) International Filing Date: 28 June 2002 (28.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/301,410 29 June 2001 (29.06.2001) US

(71) Applicant (for all designated States except US): **AB SCIENCE** [FR/FR]; 3, avenue Georges V, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain** [FR/FR]; 22 bis, passage Dauphine, F-75006 Paris (FR).
KINET, Jean-Pierre [FR/US]; 2 Hunt Road, Lexington, MA 02173 (US).

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:


- with international search report

(88) Date of publication of the international search report:
25 September 2003

[Continued on next page]

(54) Title: USE OF TYROSINE KINASE INHIBITORS FOR TREATING INFLAMMATORY DISEASES

Ankle thickness (1.5 mg/daily)



(57) Abstract: The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Inte al Application No
PL 71B 02/03301

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/00 A61K31/404 A61K31/506 A61K31/505 A61K31/519
A61K31/517 A61K31/498 A61K31/415 A61K31/4709 A61K31/015
A61K31/095 A61K31/66 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, SCISEARCH, EMBASE, MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 45689 A (SUGEN INC ;LIPSON KEN (US); MCMAHON GERALD (US)) 28 June 2001 (2001-06-28) page 4, line 10 - line 19 page 23, line 14 - line 17 ---	1-6, 9-12, 27-31
X	US 5 792 783 A (TANG PENG CHO ET AL) 11 August 1998 (1998-08-11) claims 15-17,20-24,27 ---	1-6, 9-12, 27-31
X	WO 00 56709 A (MILLER TODD ANTHONY ;LIANG CONGXIN (US); SUGEN INC (US); TANG PENG) 28 September 2000 (2000-09-28) claims 1,7,18,21,22,26-28,34,35,37-39 ---	1-6, 9-12, 27-31
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 December 2002

Date of mailing of the international search report

01.04.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van der Kooij, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03301

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 133 305 A (TANG PENG CHO ET AL) 17 October 2000 (2000-10-17) column 5, line 3 - line 8 column 70, line 59 - line 67 column 71, line 32 - line 38 column 75, line 6 -column 78, line 51 claims 1,5-8,13,17,27 ---	1-6, 9-12, 27-31
X	WO 99 61422 A (SUGEN INC) 2 December 1999 (1999-12-02) page 31, line 12 - line 17 page 34, line 1 - line 6 page 46, line 24 - line 32 page 57, line 9 -page 65, line 26 claims 1,13-16,18,21 ---	1-6, 9-12, 27-31
X	WO 99 21859 A (GLAXO GROUP LTD ;GLENNON KIMBERLY CAROLINE (US); PEEL MICHAEL ROBE) 6 May 1999 (1999-05-06) page 29, line 27 -page 30, line 3 page 30, line 14 - line 25 claims 1-21,23,26,32,34,40 ---	1-6, 9-12, 27-31
X	WO 98 50356 A (SUGEN INC) 12 November 1998 (1998-11-12) page 113, line 4 - line 13 page 116, line 3 - line 21 claims 1-45,50-52,66 ---	1-6, 9-12, 27-31
X	DE 198 24 922 A (BOEHRINGER INGELHEIM PHARMA) 9 December 1999 (1999-12-09) page 8, line 17 - line 25 claims 1-9 ---	1-6, 9-12, 27-31
X	DE 198 44 003 A (BOEHRINGER INGELHEIM PHARMA) 30 March 2000 (2000-03-30) page 8, line 61 -page 9, line 2 claims 1-8 ---	1-6, 9-12, 27-31
X	WO 01 16130 A (SPEVAK WALTER ;MEEL JACOBUS C A VAN (AT); TONTSCH GRUNT ULRIKE (AT) 8 March 2001 (2001-03-08) page 34, paragraph 2 page 35, paragraph 2 claims 1-10 ---	1-6, 9-12, 27-31

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03301

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MOHAMMADI MOOSA ET AL: "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors." SCIENCE (WASHINGTON D C), vol. 276, no. 5314, 1997, pages 955-960, XP002065235 ISSN: 0036-8075 the whole document -----</p>	<p>1-6, 9-12, 27-31</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 172 B 02/03301

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0145689	A	28-06-2001	AU 3436301 A	03-07-2001
			EP 1255536 A2	13-11-2002
			WO 0145689 A2	28-06-2001
			US 2002010203 A1	24-01-2002

US 5792783	A	11-08-1998	US 5880141 A	09-03-1999
			US 6316635 B1	13-11-2001
			US 2002102608 A1	01-08-2002
			AT 200863 T	15-05-2001
			AU 706597 B2	17-06-1999
			AU 6044196 A	30-12-1996
			BR 9606410 A	30-12-1997
			CA 2192797 A1	19-12-1996
			DE 29623744 U1	30-09-1999
			DE 69612649 D1	07-06-2001
			DE 69612649 T2	31-10-2001
			DK 769947 T3	13-08-2001
			EP 0769947 A1	02-05-1997
			EP 0934931 A2	11-08-1999
			ES 2159741 T3	16-10-2001
			GR 3036315 T3	31-10-2001
			HK 1011933 A1	18-01-2002
			HU 9701694 A2	28-06-1999
			JP 2000026412 A	25-01-2000
			JP 10504323 T	28-04-1998
			JP 3231044 B2	19-11-2001
			NO 965377 A	12-02-1997
			NZ 310109 A	28-01-1999
			PT 769947 T	31-10-2001
			WO 9640116 A1	19-12-1996
			US 6225335 B1	01-05-2001
			US 5883116 A	16-03-1999
			US 5834504 A	10-11-1998
			US 5886020 A	23-03-1999
			US 5883113 A	16-03-1999
			US 2001027207 A1	04-10-2001

WO 0056709	A	28-09-2000	AU 3770000 A	09-10-2000
			EP 1165513 A1	02-01-2002
			JP 2002540096 T	26-11-2002
			WO 0056709 A1	28-09-2000

US 6133305	A	17-10-2000	US 2001007033 A1	05-07-2001
			US 2002026053 A1	28-02-2002
			AU 7661498 A	27-11-1998
			EP 0984930 A1	15-03-2000
			JP 2002511852 T	16-04-2002
			WO 9850356 A1	12-11-1998

WO 9961422	A	02-12-1999	AU 4410299 A	13-12-1999
			BR 9910792 A	29-01-2002
			CA 2314156 A1	02-12-1999
			CN 1311775 T	05-09-2001
			EP 1082305 A1	14-03-2001
			HU 0103617 A2	28-02-2002
			JP 2002516310 T	04-06-2002
			NO 20005916 A	29-01-2001
			PL 344477 A1	05-11-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 1B 02/03301

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9961422	A		SK 18062000 A3	11-06-2001
			TR 200003514 T2	21-05-2002
			WO 9961422 A1	02-12-1999
			US 6395734 B1	28-05-2002
WO 9921859	A	06-05-1999	AU 1151099 A	17-05-1999
			WO 9921859 A1	06-05-1999
			ZA 9809249 A	10-04-2000
WO 9850356	A	12-11-1998	AU 7684298 A	27-11-1998
			EP 0984930 A1	15-03-2000
			JP 2002511852 T	16-04-2002
			US 6316429 B1	13-11-2001
			WO 9850356 A1	12-11-1998
			US 6486185 B1	26-11-2002
			US 2002156083 A1	24-10-2002
			US 2002183370 A1	05-12-2002
			US 6051593 A	18-04-2000
			US 2001056094 A1	27-12-2001
			US 6313158 B1	06-11-2001
			US 2002058661 A1	16-05-2002
			US 6130238 A	10-10-2000
			US 6114371 A	05-09-2000
			AU 7661498 A	27-11-1998
			US 6133305 A	17-10-2000
			US 2001007033 A1	05-07-2001
			US 2002026053 A1	28-02-2002
DE 19824922	A	09-12-1999	DE 19824922 A1	09-12-1999
			AU 4370799 A	20-12-1999
			BG 104938 A	29-06-2001
			BR 9910898 A	13-02-2001
			CA 2328291 A1	09-12-1999
			CN 1303374 T	11-07-2001
			EE 200000723 A	15-04-2002
			WO 9962882 A1	09-12-1999
			EP 1100779 A1	23-05-2001
			HR 20000831 A1	31-12-2001
			HU 0102210 A2	28-11-2001
			JP 2002516906 T	11-06-2002
			NO 20006138 A	01-02-2001
			PL 344467 A1	05-11-2001
			SK 18222000 A3	06-08-2001
			TR 200003515 T2	21-06-2001
			US 6319918 B1	20-11-2001
DE 19844003	A	30-03-2000	DE 19844003 A1	30-03-2000
			AU 6086399 A	17-04-2000
			BG 105327 A	31-12-2001
			BR 9914065 A	19-06-2001
			CA 2342622 A1	06-04-2000
			CN 1319090 T	24-10-2001
			EE 200100184 A	15-08-2002
			WO 0018734 A1	06-04-2000
			EP 1115704 A1	18-07-2001
			HR 20010216 A1	30-04-2002
			HU 0104973 A2	29-04-2002
			JP 2002525356 T	13-08-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/03301

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
DE 19844003	A	NO 20011477 A	22-03-2001	
		PL 346898 A1	11-03-2002	
		SK 4032001 A3	06-11-2001	
		TR 200100854 T2	21-12-2001	

WO 0116130	A	08-03-2001	DE 19940829 A1	01-03-2001
			DE 10029285 A1	20-12-2001
			AU 6998000 A	26-03-2001
			WO 0116130 A1	08-03-2001
			EP 1212318 A1	12-06-2002
